Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Indoco Remedies Gets USFDA Nod to Market Lofexidine Tablets with 180 Days Exclusivity
Details : Lofexidine is a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Brand Name : Lucemyra-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2024
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : US WorldMeds
Deal Size : Undisclosed
Deal Type : Partnership
US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic
Details : US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.
Brand Name : Lucemyra
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Lofexidine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : US WorldMeds
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?